Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614428 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7616275 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7616873 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7644393 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7617350 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7620617 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7623018 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7614205 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7620390 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 | |
| SCHEMBL7614252 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458826-B2 | A PYRROLIDINE COMPOUND USED AS REPELLANT FOR PESTS, INSECTS, MITES AND TICKS ON ANIMALS AND HUMAN | NAVARTIS ANIMAL HEALTH US, INC. | 2002-10-01 | — | — | US | claimed |
| EP-1087660-B1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 2002-08-07 | — | — | EP | claimed |
| US-20010002402-A1 | A pyrrolidine compound used as repellant for pests, insects, mites and ticks on animals and human | NOVARTIS ANIMAL HEALTH US, INC. | 2001-05-31 | — | — | US | claimed |
| EP-1087660-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | Novartis AG (Novartis SA) (Novartis Inc.) (CH) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065308-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 1999-12-23 | — | — | WO | claimed |
| US-6458826-B2 | A PYRROLIDINE COMPOUND USED AS REPELLANT FOR PESTS, INSECTS, MITES AND TICKS ON ANIMALS AND HUMAN | NAVARTIS ANIMAL HEALTH US, INC. | 2002-10-01 | — | — | US | disclosed |
| EP-1087660-B1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 2002-08-07 | — | — | EP | disclosed |
| US-20010002402-A1 | A pyrrolidine compound used as repellant for pests, insects, mites and ticks on animals and human | NOVARTIS ANIMAL HEALTH US, INC. | 2001-05-31 | — | — | US | disclosed |
| EP-1087660-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | Novartis AG (Novartis SA) (Novartis Inc.) (CH) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065308-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010002402-A1 | A pyrrolidine compound used as repellant for pests, insects, mites and ticks on animals and human | NISCH, DDT, PIR | SLC6A2 4086/4885SLC6A4 4807/4885SLC6A3 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.